InCred Asset Management, a prominent fund manager, is placing its highest conviction on domestic healthcare companies, particularly Healthcare Global (HCG), Thyrocare, and FDC. Aditya Khemka, CIO at InCred AMC, highlighted that the firm's portfolio weighting reflects its strongest beliefs, with HCG holding the top spot.
Focus on Domestic Healthcare Plays
InCred AMC's investment strategy explicitly favors Indian-centric healthcare businesses, including hospitals, diagnostics, and branded pharmaceutical companies. This approach is a deliberate shift away from export-led names, which are often exposed to greater regulatory uncertainty and tariff risks in international markets.
Khemka emphasized that while some holdings experienced a muted performance over the last six months, the firm's long-term conviction remains steadfast. The investment horizon for these picks is typically 12-24 months, and sometimes up to 36 months, rather than short-term price movements.
Top Conviction: HCG, Thyrocare, and FDC
- Healthcare Global (HCG): Identified as InCred's highest conviction idea, HCG's significant portfolio weight underscores the firm's confidence in its long-term potential.
- Thyrocare: Following HCG, Thyrocare represents the second-highest conviction pick, aligning with the strategy of investing in predictable, non-discretionary healthcare demand.
- FDC: Despite recent underperformance phases, FDC is the third key stock, fitting InCred's view on structurally durable domestic franchises within the branded pharma segment.
According to Khemka, alpha generation in active management stems from backing the strongest ideas with substantial capital. When a company performs well after being sized appropriately, it contributes significantly to outperforming broader market indices.
Risk Management and Exiting Weak Theses
Beyond identifying strong prospects, InCred AMC maintains a disciplined approach to risk control. The firm is prepared to cut exposure and exit companies if their underlying thesis weakens structurally, even if the broader sector remains attractive. Khemka cited Cngene as an example, where despite initial optimism, the business failed to meet expectations, leading to its exit from the portfolio.
Capital from such exits is then redeployed into opportunities with a more structural and sound growth narrative, ensuring efficient allocation and adherence to the investment philosophy.
Implications for Investors
This strategy offers valuable insights for investors navigating the healthcare and pharmaceutical sectors. In a market that is increasingly selective, InCred's approach highlights that stock-specific execution and visible earnings pathways in domestic businesses are paramount. It suggests a focus on concentrated bets within the Indian healthcare landscape, with a readiness to adapt swiftly when investment theses no longer hold true.